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ABSTRACT
Chromosome instability (CIN) in solid tumours results in multiple numerical and 
structural chromosomal aberrations and is associated with poor prognosis in multiple 
tumour types. Recent evidence demonstrated CEP17 duplication, a CIN marker, is a 
predictive marker of anthracycline benefit. An analysis of the BR9601 and MA.5 clinical 
trials was performed to test the role of existing CIN gene expression signatures as 
predictive markers of anthracycline sensitivity in breast cancer. 
Univariate analysis demonstrated, high CIN25 expression score was associated 
with improved distant relapse free survival (DRFS) (HR: 0.74, 95% CI 0.54-0.99, p 
= 0.046). High tumour CIN70 and CIN25 scores were associated with aggressive 
clinicopathological phenotype and increased sensitivity to anthracycline therapy 
compared to low CIN scores. However, in a prospectively planned multivariate analysis 
only pathological grade, nodal status and tumour size were significant predictors of 
outcome for CIN25/CIN70. A limited gene signature was generated, patients with low 
tumour CIN4 scores benefited from anthracycline treatment significantly more than 
those with high CIN4 scores (HR 0.37, 95% CI 0.20-0.56, p = 0.001). In multivariate 
analyses the treatment by marker interaction for CIN4/anthracyclines demonstrated 
hazard ratio of 0.35 (95% CI 0.15-0.80, p = 0.012) for DRFS. This data shows CIN4 
is independent predictor of anthracycline benefit for DRFS in breast cancer. 
INTRODUCTION
Meta-analyses performed by the Early Breast 
Cancer Trialists Collaborative Group (EBCTCG) 
confirm a significant increase in disease free and overall 
survival (OS) following the addition of anthracyclines 
to polychemotherapy [1]. Anthracyclines, however, 
cause significant toxicities including life threatening 
cardiotoxicity and leukaemia [2-4]. Selecting the subset 
of patients who will benefit from adjuvant anthracycline 
whilst sparing other patients unnecessary toxicities 
remains a clinically highly relevant approach for early 
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breast cancer. Significant resources have been devoted 
to developing markers that may predict anthracycline 
benefit (HER2, TOP2A, Ch17CEP and TIMP1) with 
limited success [5-9]. To date Ch17CEP (duplication of 
the peri-centromeric α-satellite region of chromosome 
17) and TOP2A are the only markers that have shown 
consistent results across a number of clinical trials [7-9]. 
The functional pathways related to anthracycline benefit 
in Ch17CEP/TOP2A altered tumours remain unknown. 
Research from our group has linked the predictive effect 
of CEP17 in vivo to chromosome instability (CIN), which 
itself is predictive of anthracycline benefit in the BR9601 
trial [10] and in preclinical models.
CIN is a phenotype description of genomic 
instability at the karyotypic level that results in multiple 
alterations in chromosomal number or structure. Multiple 
mechanisms drive CIN, including compromised spindle 
assembly checkpoint (SAC), sister chromatid cohesion 
defects, additional centrosomes and abnormal spindle 
kinetochore attachments. Pre-mitotic mechanisms may 
also include defects in DNA repair and replication 
pathways. CIN is associated with poor prognosis in many 
patients with solid tumours [11-12]. Critically for the 
current study, cell lines with high CIN phenotype enter 
mitotic catastrophe if challenged with anthracyclines, 
possibly as a result of defective SAC and other G2/M 
checkpoints [13]. In silico analysis has identified two 
mRNA signatures associated with CIN, “CIN25” and 
“CIN70”, as predictive of prognosis in a number of 
cancer datasets [14]. Furthermore high CIN70 signature 
expression was associated with paclitaxel resistance in 
ovarian cancers [15]. The CIN70 signature incorporates 
many genes whose mRNA expression levels correlate with 
proliferation, and have a role in the cell cycle [11]. 
Our work and that of others support a link 
between SAC dysregulation, a potential cause of CIN, 
CIN itself [10] and markers of CIN [7-9] and benefit 
from anthracycline containing polychemotherapy in 
vivo. Preclinical evidence linking CIN to anthracycline 
sensitivity support our hypothesis that CIN provides a 
potential clinically useful and relevant means of selecting 
those patients who are likely to benefit from anthracycline 
containing chemotherapy. Successful validation of such 
an approach would further support the selective use of 
anthracycline based chemotherapy and provide a viable 
diagnostic approach to support such selective use. 
To further validate the role of existing CIN gene 
expression signatures as markers of anthracycline 
sensitivity we assessed these gene expression signatures 
in a prospectively planned and powered retrospective 
analysis of two pivotal clinical trials (BR9601 and 
MA.5). In addition we identified a new minimal gene 
set encapsulating the predictive value of these assay 
and validated its ability to stratify patients according to 
anthracycline benefit using clinical outcome.
RESULTS
Correlation of CIN25 and 70 and 
clinicopathological parameters with clinical 
outcomes
We successfully analysed 282 of 321 (87.9%) and 
421 of 440 (95.7%) tumours from BR9601 and MA.5, 
respectively. High CIN25 and CIN70 scores were defined 
as above the median as previously described. In univariate 
analysis using continuous clinicopathological biomarkers, 
high CIN25 and CIN70 scores were associated with 
younger age (p < 0.0001), high tumour grade (p < 0.0001), 
PgR negativity (p < 0.0001) and ER negativity (p < 
0.0001) but not with tumour size, nodal status or HER2 
status.
CIN signatures as prognostic markers for OS and 
DRFS
In a preplanned analysis the prognostic significance 
of CIN25 and CIN70 was tested on the entire patient 
cohort, irrespective of allocated adjuvant chemotherapy or 
trial. No significant association between CIN70 expression 
and DRFS (HR: 1.14, 95% CI 0.91-1.43, p = 0.273) or 
OS (HR: 1.14, 95% CI 0.88-1.45, p = 0.278) was evident. 
By contrast, tumours with high CIN25 scores were 
associated with reduced DRFS (HR: 1.43, 95%CI 1.11-
1.67, p = 0.004, Figure 2A) and OS (HR: 1.45, 95%CI 
1.14-1.85, p = 0.003, Figure 2B). After multivariate 
analysis and adjustment for nodal status, grade, size, age, 
HER2, ER and PgR status, a high CIN25 score was not an 
independent predictor for DRFS or OS.
CIN signatures as predictive markers of 
anthracycline benefit
In a preplanned analysis no significant differential 
benefit in either DRFS or OS from E-CMF treatment 
was demonstrated in univariate analysis between patients 
whose tumours had high or low CIN70 expression (Table 
1).
In univariate analysis, patients whose tumours had 
high CIN25 gene expression scores had an increased 
DRFS (HR: 0.74, 95%CI 0.54-0.99, p = 0.046) when 
treated with E-CMF compared with patients treated with 
CMF alone (Table 1); a similar association was seen 
with respect to OS, although this did not reach statistical 
significance (HR: 0.76, 95%CI 0.56-1.05, p = 0.095). 
Conversely, there was no apparent differential benefit of 
E-CMF vs. CMF in patients with low CIN25 scores for 
DRFS (HR: 0.85, 95%CI 0.61-1.21, p = 0.374) or OS (HR: 
0.87, 95%CI 0.61-1.29, p = 0.535). A multivariate analysis 
Oncotarget31695www.impactjournals.com/oncotarget
Table 1: Hazard ratios for overall survival and distant relapse free survival comparing epirubicin plus cyclophosphamide, 
methotrexate and fluorouracil [E-CMF] with CMF alone by biomarker status.
Figure 1: Schematic REMARK diagram representing the BR9601 and MA.5 cohorts.
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with adjustment for size, nodal status, ER, pathological 
grade, HER2, CIN25, treatment and CIN25 by treatment 
interaction showed only pathological grade, nodal status, 
tumour size and CEP17 to be significant predictors of 
outcome (Table 1). 
The hazard ratio for the treatment by marker effect 
of CIN25 was 0.86 (95% CI 0.54-1.36, p = 0.519) for 
DRFS and 0.86 (95% CI 0.53-1.40, p = 0.549) for OS 
(Table 1).
CIN signature as a biological marker for 
anthracycline therapy in grade III patients
Previous research identified a significant association 
between CIN gene expression and grade III tumours 
[9]; therefore, an exploratory analysis was performed in 
patients with grade III tumours. In univariate analysis, 
patients with grade III tumours that had high CIN25 gene 
expression scores had longer DRFS (HR: 0.66, 96%CI 
0.46-0.94, p = 0.021) and OS (HR: 0.70, 95%CI 0.49-
1.00, p = 0.05) when treated with E-CMF than those 
treated with CMF alone (Figure 3, Table 1). By contrast, 
no significant benefit from E-CMF treatment versus CMF 
treatment was demonstrated in patients whose tumours 
were grade 3 and had low CIN25 gene expression (Table 
1). No significant benefit from adjuvant E-CMF versus 
CMF was demonstrated in patients with grade I and II 
tumours irrespective of CIN25 gene expression scores 
(Table 1). 
The uncorrected hazard ratio for treatment by 
marker effect of CIN25 in grade III tumours was 0.81 
(95% CI 0.45-1.46, p = 0.479) for DRFS and 0.78 (95% 
CI 0.42-1.43, p = 0.413) for OS (Table 1).
CIN4 as a predictor for anthracycline benefit
In order to select a minimal set of genes that reflects 
CIN we used the merged clinical cohort (containing both 
BR9601 and MA.5) and applied a bootstrap aggregation 
approach to allow a training and validation approach to be 
tested (see methods). 
A CIN4 score was generated using the expression 
values of 4 genes, HDGF, KIAA0286, RFC4 and MSH6, 
weighted by their regression coefficients. Patients with 
Table 2: Multivariate analysis for DRFS and OS. 
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Figure 2: Kaplan-Meier survival curves for low CIN25 score [red line] and high CIN25 score (blue line) for distant 
relapse free survival (A) and overall survival (B).
Figure 4: Kaplan-Meier survival curve for low CIN4 score treated with epirubicin plus cyclophosphamide, methotrexate 
and fluorouracil (E-CMF) (orange line), high CIN4 score treated with E-CMF (red line), low CIN4 score treated with 
CMF (light blue line) and high CIN4 score treated with CMF (dark blue line) for distant relapse free survival for 
overall survival (A) and distant relapse free survival (B).
Figure 3: Kaplan-Meier survival curves for epirubicin plus cyclophosphamide, methotrexate and fluorouracil 
(E-CMF) treated low CIN25 (orange), E-CMF high CIN25 (red), CMF treated low CIN25 (light blue), and CMF high 
CIN25 (dark blue) for distant relapse free survival (A) overall survival (B) 
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cancers that have a low CIN4 score had superior DRFS 
(HR 2.72, 95%CI 1.48-5.02, p =  0.001) and OS (HR 
2.00, 95%CI 1.09-3.69, p = 0.03) when treated with the 
anthracycline compared to CMF alone (Figure 4). In 
multivariate analysis, the hazard ratio for treatment marker 
effect of CIN4 was 0.35 (95% CI 0.15-0.79, p = 0.01) for 
DRFS and 0.35 (95%CI 0.15-0.80, p = 0.01) (Table 2).
DISCUSSION
Chromosome segregation is a tightly orchestrated 
process and when this process goes awry CIN and 
aneuploidy results [16]. The original CIN signature 
produced by Carter and colleagues used aneuploidy as a 
surrogate marker for CIN and both this and mRNA CIN 
signatures were associated with poor prognosis in multiple 
cancers [11-12]. Furthermore, a study performed by Szasz 
and colleagues identified a four gene signature, AURKA, 
FOXM1, TOP2A and TPX2 from the CIN70 signature 
based on the high level of correlation with histological 
grade and in silico expression [17]. Their four gene score 
was able to stratify grade 2 breast cancer patients into 
good and poor prognostics cohorts even better than Ki67 
and the mitotic index [17]. CIN has also been linked to 
sensitivity to specific chemotherapy agents, including 
anthracyclines [10]. In this study we examined the role 
of CIN gene signatures as predictive biomarkers for 
anthracycline benefit in breast cancer. 
In a prospectively planned molecular analysis 
of two retrospective anthracycline trials univariate 
analyses and an analysis including stratification by 
grade, data for the CIN25 signature further supported 
our hypothesis that CIN is associated with anthracycline 
sensitivity in early breast cancer. However we were 
unable to demonstrate statistically significant predictive 
value for the predefined CIN25 and CIN70 signatures 
in multivariate regression analyses, when correcting 
for conventional prognostic markers and including the 
previously validated CEP17 predictive biomarker [10-7]. 
Several studies have demonstrated correlations between 
grade and chromosomal instability [10-18-19]. Moreover, 
low and intermediate grade tumours have fewer structural 
genomic aberrations and numerical aberrations in whole 
chromosomes [18-20], perhaps reflecting a reduced 
incidence of CIN. This may explain why, in our study 
there appeared to be benefit from the addition of an 
anthracycline in patients with high grade tumours and high 
CIN25 signature but not those with grade 1 and 2 tumours. 
To validate the observed effect of CIN25 as a predictor of 
anthracycline sensitivity in an independent dataset with 
80% power at the p = 0.05 level we would require a 2470 
patients.
We also used a training and validation approach to 
derive a novel, minimum 4 gene signature “CIN4” (US 
patent number 62/024,729) as a predictive biomarker 
for anthracycline benefit. Using genes within the CIN70 
gene panel and a combination of expression clustering, 
bootstrap aggregation and Cox regression modelling, we 
were able to identify a set of 4 genes, HDGF, KIAA0286, 
RFC4 and MSH6 which were significantly predictive of 
anthracycline benefit. Our study demonstrated that high 
CIN4 score was associated with improved DRFS in 
patients treated with anthracycline therapy. 
There are a number of multigene signatures 
associated with prognosis available commercially [21], 
some of which are being tested in prospective randomized 
trials such as “Microarray in Node-Negative Disease May 
Avoid Chemotherapy Trial” (MINDACT) [22] and “Trial 
Assigning Individualised Options for Treatment (Rx)” 
(TAILORx) [23]; both studies are assessing whether it 
is possible to avoid the use of chemotherapy in patients 
predicted not to benefit. However, no signatures that 
are specifically associated with benefit from specific 
chemotherapy agents have been validated to level I 
evidence as described by Simon et al [24]. At this point 
it still remains largely unclear which subpopulation of 
patients will benefit from adjuvant anthracycline therapy 
and which patients are being treated unnecessarily. 
Therefore a validated diagnostic test is urgently required 
to identify which subgroup of patients should be treated 
with anthracycline and which should be offered alternative 
therapies. The CIN4 signature identified in this study is a 
credible candidate to address this specific challenge.
Our CIN4 gene signature differs from existing 
candidates in being an independent predictor of 
anthracycline benefit. Interestingly, three of the four 
genes in our CIN4 signature are involved in DNA repair/
DNA-binding activity. Anthracyclines are thought to 
exert their actions by intercalation with DNA, generation 
of free radicals and crosslinking DNA to proteins [25]. 
Therefore, dysregulation of genes involved in DNA repair 
may plausibly lead to anthracycline sensitivity. To validate 
this gene signature in an independent dataset with 80% 
power at the p = 0.05 level would require only 300 patients 
treated in an adjuvant anthracycline trial. In conclusion 
we have demonstrated that a 4 gene signature, related to 





The BR9601 trial recruited 374 pre- and 
post-menopausal women with completely excised, 
histologically confirmed breast cancer and a clear 
indication for adjuvant chemotherapy. Patients 
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were randomized between 8 cycles of CMF (i.v. 
cyclophosphamide 750 mg/m2, methotrexate 50 mg/
m2 and 5-fluorouracil 600 mg/m2) every 21 days, and 
E-CMF (4 cycles of epirubicin 100 mg/m2 every 21 days 
followed by 4 cycles of the same CMF regimen ); patient 
characteristics are shown in supplementary data (Figure 
1, Supplementary Table 1). The protocol was approved 
by central and local ethics committees, and each patient 
provided written informed consent prior to randomization. 
For the current analysis, tissue blocks were retrieved and 
RNA was extracted. The primary outcomes of the BR9601 
study were RFS and OS, however distant relapse free 
survival was also reported .
MA.5 trial
The MA.5 trial randomized 716 premenopausal 
women with node-positive breast cancer to receive 
either adjuvant CEF or CMF (Figure 1, Supplementary 
Table 1). The CEF regimen consisted of 6 cycles of 
epirubicin 60 mg/m2 and 5-fluorouracil (5-FU) 500 mg/
m2, both delivered intravenously on days 1 and 8, and oral 
cyclophosphamide 75 mg/m2 daily on days 1 through 14. 
Patients randomized to the CEF regimen also received 
antibiotic prophylaxis throughout. The CMF regimen 
consisted of 6 cycles of methotrexate 40 mg/m2 and 5-FU 
600 mg/m2, both delivered intravenously on days 1 and 
8, and oral cyclophosphamide 100 mg/m2 daily on days 
1 through 14. The MA.5 protocol was approved by the 
institutional review board at each participating center 
and registered as NCI-V90-0027 on cancer.gov. Written 
informed consent was obtained from each woman. 
RNA extraction
Total RNA from FFPE tissue samples (2 x 10µM 
full sections) were extracted using the RecoverAll Total 
Nucleic Acid Isolation kit (Life Technologies) according 
to the manufacturers protocol and concentrations 
were determined using the NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies).
Gene expression analysis
RNA (400ng) was used with the nCounter system, 
according to the manufacturer’s protocol (NanoString ® 
Technologies, Seattle, WA, USA). In brief, 5µl of RNA 
was hybridized at 96oC overnight with the NanoString 
Codeset. Probes for the analysis of test genes and controls 
were synthesized by NanoString technologies, including 
probes for the 70 genes of interest and 6 normalising genes 
(Supplementary Table 2). All 76 genes and controls were 
assayed simultaneously in multiplexed reactions. After 
probe hybridizations and NanoString nCounter digital 
reading, counts for each RNA species were extracted and 
analyzed. The nCounter CodeSet contains two types of 
built-in controls: positive controls (spiked RNA at various 
concentrations to assess the overall assay performance) 
and negative controls (probes for background calculation). 
The raw data were normalized to the standard curve 
generated via the nCounter system spike-in controls 
present in all reactions.
Statistics
The SPSS (v20) statistical package was used for 
statistical analysis. Kaplan-Meier estimates of survival 
were used for analysis of distant relapse free (DRFS) 
and overall survival (OS). The Cox’s proportional hazard 
model was used to obtain hazard ratios for relapse or 
death. When comparing outcomes between the treatment 
arms within the groups of patients identified by biomarker 
expression, p-values were not calculated for sub-groups 
to avoid multiple testing and bias where one group was 
much smaller than the other. The Cox model was instead 
used to identify statistically significant interactions (p < 
0.05) between biomarkers and outcome on the different 
treatments (treatment by marker effect), in models that 
also included biomarker status (marker effect) and 
treatment, as covariates. For the CIN25 and CIN70 
signatures values were dichotomised around the median 
as previously described and a combined, preplanned 
treatment by marker analysis was performed using results 
from both the BR9601 and MA5 clinical trial cohorts.
Development of a 4 gene predictive signature
The combined BR9601/MA5 cohort was split to 
two groups according to the randomized treatment. Using 
Affinity propagation clustering (R package apcluster1), 
the 70 genes were clustered into 9 groups according to 
their expression profiles (Supplementary Figure 2). A 
multivariate Cox model was fitted for each gene, adjusting 
for clinical variables including HER2, ER, PgR, tumour 
size, grade and nodal status. The top genes from each 
expression cluster, with the most significant p-value in 
the anthracycline treated cohort and a non-significant 
CMF cohort, were selected to make a list of 21 genes 
(Supplementary Figure 1). The number of genes selected 
from each cluster was weighted by the size of the cluster; 
as a result, more genes were selected for large clusters 
compared to small clusters (Supplementary Table 4). Each 
cluster had to be represented at least once even if the gene 
in that cluster was not significant. The gene breakdown 
for clusters 1-9 was as follows: CDC2; KIF20A; HDGF; 
MDUFAB1, CDC3A; CDC6, MAD2L1, NXT1, TOPK; 
FEN1, CCT5; DKC1, ECT2; KIAA0286, MCM2, RFC4, 
MSH6; ch.TOG, CNAP1, TOP2A, RRM1 (Supplementary 
Table 4). From this list, all possible combinations of 2, 
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3, 4 and 5 gene signatures were examined (210, 1330, 
5985, and 20349 combinations respectively). Using 
bootstrapped aggregation (bagging), each combination 
was bootstrapped 100 times, with the median area 
under the curve (AUC) noted as the bagged variable. In 
each bootstrap, the treatment cohort was split into 60% 
training and 40% test sets [26-27-28-29]. The AUC was 
calculated from the test sets (R package survivalROC2) 
(Supplementary Table 5). The gene signature selected 
had the greatest AUC for a treatment by marker effect in 
both the training and validation approaches and included 
four genes, HDGF, KIAA0286, RFC4 and MSH6, termed 
the CIN4 signature. A multivariate Cox regression was 
fitted using the four genes, adjusting for the same clinical 
variables mentioned above (Supplementary Table 6). A 
CIN4 score was generated using the expression values of 
the four genes, weighted by their regression coefficients. 
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